image
Healthcare - Biotechnology - NASDAQ - US
$ 3.56
3.49 %
$ 3.09 M
Market Cap
-0.27
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one PTIX stock under the worst case scenario is HIDDEN Compared to the current market price of 3.56 USD, Protagenic Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one PTIX stock under the base case scenario is HIDDEN Compared to the current market price of 3.56 USD, Protagenic Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one PTIX stock under the best case scenario is HIDDEN Compared to the current market price of 3.56 USD, Protagenic Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PTIX

image
$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.0$3.0$3.0$2.0$2.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
0 REVENUE
0.00%
-5.7 M OPERATING INCOME
-25.93%
-5.53 M NET INCOME
-10.50%
-4.22 M OPERATING CASH FLOW
-13.84%
2.8 M INVESTING CASH FLOW
-41.31%
1.96 M FINANCING CASH FLOW
0.00%
0 REVENUE
0.00%
-1.45 M OPERATING INCOME
11.87%
-1.44 M NET INCOME
7.32%
-1.07 M OPERATING CASH FLOW
-30.28%
0 INVESTING CASH FLOW
0.00%
103 K FINANCING CASH FLOW
-93.60%
Balance Sheet Protagenic Therapeutics, Inc.
image
Current Assets 1.88 M
Cash & Short-Term Investments 1.84 M
Receivables 0
Other Current Assets 44.4 K
Non-Current Assets 73 K
Long-Term Investments 0
PP&E 73 K
Other Non-Current Assets 0
94.00 %3.73 %Total Assets$2.0m
Current Liabilities 943 K
Accounts Payable 103 K
Short-Term Debt 0
Other Current Liabilities 840 K
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
10.92 %89.08 %Total Liabilities$942.8k
EFFICIENCY
Earnings Waterfall Protagenic Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 50.3 K
Gross Profit 0
Operating Expenses 5.7 M
Operating Income -5.7 M
Other Expenses -176 K
Net Income -5.53 M
00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)0(50k)0(6m)(6m)176k(6m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-545.36% ROE
-545.36%
-282.49% ROA
-282.49%
-562.69% ROIC
-562.69%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Protagenic Therapeutics, Inc.
image
00(500k)(500k)(1m)(1m)(1m)(1m)(2m)(2m)(2m)(2m)(3m)(3m)(3m)(3m)(4m)(4m)(4m)(4m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -5.53 M
Depreciation & Amortization 50.3 K
Capital Expenditures 0
Stock-Based Compensation 923 K
Change in Working Capital 468 K
Others 335 K
Free Cash Flow -4.22 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Protagenic Therapeutics, Inc.
image
PTIX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Protagenic Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") announced today that warrant exchanges and exercises over the last four trading days have generated $3.1 million in cash. The proceeds will fund working-capital needs and advance the Company's peptide-based drug candidates for stress-related and central-nervous-system disorders. accessnewswire.com - 1 month ago
Gold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday. benzinga.com - 1 month ago
PTIX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Protagenic Therapeutics, Inc. Is Fair to Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Protagenic Therapeutics, Inc. (NASDAQ: PTIX) and Phytanix Bio Inc. is fair to Protagenic shareholders. Upon completion of the proposed transaction, Protagenic shareholders are expected to own approximately 35% of the combined company. Halper Sadeh encourages Protagenic shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Hal. businesswire.com - 1 month ago
Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders NEW YORK, NY AND SANTA BARBARA, CA / ACCESS Newswire / May 19, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") and Phytanix Bio Inc. have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction (the "Combination"). The combined entity, to be called Phytanix, Inc., will bring together two pipelines focused on stress-related and CNS disorders, five preclinical assets and one clinical-stage asset. accessnewswire.com - 1 month ago
Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, today announced that the Company's Board of Directors has approved a 1-for-14 reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share (the "Common Stock") to be effective 12:01 a.m., Eastern Time, on May 5, 2025. accessnewswire.com - 1 month ago
Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today that on November 4, 2024 it closed its previously announced private placement pursuant to a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 shares of common stock, series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen (18) months from the Stockholder Approval Date, and series B common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date for a term of five (5) years from the Stockholder Approval Date. The purchase price of each share of common stock and associated common stock purchase warrants was $0.64 ($0.89 in the case of insiders). accesswire.com - 7 months ago
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today it has entered into a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 shares of common stock (or pre-funded warrants in lieu of shares of common stock), series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen (18) months from the Stockholder Approval Date (as defined in the Purchase Agreement), and series B common stock purchase warrants to purchase an aggregate of 1,948,295 shares of Common Stock with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date for a term of five (5) years from the Stockholder Approval Date. The purchase price of each share of common stock and associated common stock purchase warrants will be $0.64 ($0.89 in the case of insiders). accesswire.com - 7 months ago
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion of its Phase 1 trial involving PT00114, its synthetic stress-regulating peptide, for treating neuropsychiatric disorders. This marks a significant milestone with the enrollment of 30 subjects across five cohorts, receiving doses up to 1,000 micrograms. accesswire.com - 1 year ago
Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical research, announced today that Dr. Andrew Slee, Chief Operating Officer, will present a talk on PT00114, the company's promising new drug candidate, at the Peptide Based Therapeutic Summit in Boston. Titled "Novel Blood-Brain Barrier Penetrating Peptide: Opening New Doors in Neuro-Psychiatric Treatment," Dr. Slee's talk will focus on the groundbreaking structure of PT00114, designed to efficiently cross the blood-brain barrier and unlock new potential in treating serious neuro-psychiatric conditions. accesswire.com - 1 year ago
Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript seekingalpha.com - 1 year ago
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results Transitioned from Pre-Clinical to Clinical Stage company in FY 2023 Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing through Phase 1 portion Plans to enroll final two out of five cohorts into the single dose portion of the Phase 1 trial within the next month NEW YORK, NY / ACCESSWIRE / April 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today provided a corporate update and reported financial results for the fourth quarter and full year 2023. "In 2023, Protagenic Therapeutics achieved a significant milestone as we began enrolling patients for our neuropeptide drug candidate, PT00114," said Dr. Garo Armen, Executive Chairman. accesswire.com - 1 year ago
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders Next clinical progress update expected in April 2024 NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, advances its mission to develop cutting-edge treatments for stress-related neuropsychiatric disorders. The company has reached another milestone by completing three out of five cohorts of healthy volunteers with PT00114, its synthetic version of the stress-regulating peptide TCAP, in a SAD Phase 1 clinical trial. accesswire.com - 1 year ago
8. Profile Summary

Protagenic Therapeutics, Inc. PTIX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 3.09 M
Dividend Yield 0.00%
Description Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
Contact 149 Fifth Avenue, New York City, NY, 10010 https://www.protagenic.com
IPO Date April 27, 2021
Employees 1
Officers Dr. Alexander Kenneth Arrow C.F.A., M.D. Chief Financial Officer & Secretary Dr. Andrew Slee Ph.D. Chief Operating Officer Dr. Garo H. Armen Ph.D. Co-Founder & Executive Chairman of the Board Dr. Robert Benjamin Stein M.D., Ph.D. Chief Medical Officer & Director